Proteomic analysis of glioblastomas: what is the best brain control sample?

UNLABELLED Glioblastoma (GB) is the most frequent and aggressive tumor of the central nervous system. There is currently growing interest in proteomic studies of GB, particularly with the aim of identifying new prognostic or therapeutic response markers. However, comparisons between different proteomic analyses of GB have revealed few common differentiated proteins. The types of control samples used to identify such proteins may in part explain the different results obtained. We therefore tried to determine which control samples would be most suitable for GB proteomic studies. We used an isotope-coded protein labeling (ICPL) method followed by mass spectrometry to reveal and compare the protein patterns of two commonly used types of control sample: GB peritumoral brain zone samples (PBZ) from six patients and epilepsy surgery brain samples (EB) pooled from three patients. The data obtained were processed using AMEN software for network analysis. We identified 197 non-redundant proteins and 35 of them were differentially expressed. Among these 35 differentially expressed proteins, six were over-expressed in PBZ and 29 in EB, showing different proteomic patterns between the two samples. Surprisingly, EB appeared to display a tumoral-like expression pattern in comparison to PBZ. In our opinion, PBZ may be more appropriate control sample for GB proteomic analysis. BIOLOGICAL SIGNIFICANCE This manuscript describes an original study in which we used an isotope-coded protein labeling method followed by mass spectrometry to identify and compare the protein patterns in two types of sample commonly used as control for glioblastoma (GB) proteomic analysis: peritumoral brain zone and brain samples obtained during surgery for epilepsy. The choice of control samples is critical for identifying new prognostic and/or diagnostic markers in GB.

[1]  D. Hayes,et al.  Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy , 2010, British Journal of Cancer.

[2]  C. Brennan,et al.  Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.

[3]  D. Hafler,et al.  Protective and therapeutic role for αB-crystallin in autoimmune demyelination , 2007, Nature.

[4]  S. Atlas,et al.  Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.

[5]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[6]  Mahlon D. Johnson,et al.  Protein Profiling in Brain Tumors Using Mass Spectrometry , 2004, Clinical Cancer Research.

[7]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Jean Mosser,et al.  Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach , 2011, Proteome Science.

[9]  Ashraf A Khalil,et al.  Biomarker discovery: A proteomic approach for brain cancer profiling , 2007, Cancer science.

[10]  Oscar Persson,et al.  Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients , 2010, Proteomics. Clinical applications.

[11]  L. Claesson‐Welsh,et al.  alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. , 2008, Blood.

[12]  P. Parsons,et al.  Alpha B‐Crystallin, a New Independent Marker for Poor Prognosis in Head and Neck Cancer , 2005, The Laryngoscope.

[13]  D. Hafler,et al.  Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. , 2007, Nature.

[14]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Vani Santosh,et al.  Differential protein expression in human gliomas and molecular insights , 2005, Proteomics.

[16]  J. David,et al.  Effects of hypoxia on stress proteins in the piglet heart at birth , 2005, Cell stress & chaperones.

[17]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[18]  C. Houser,et al.  Neuroanatomical clues to altered neuronal activity in epilepsy: From ultrastructure to signaling pathways of dentate granule cells , 2012, Epilepsia.

[19]  C. Shin,et al.  Differential Expression of Activating Transcription Factor-2 and c-Jun in the Immature and Adult Rat Hippocampus Following Lithium-Pilocarpine Induced Status Epilepticus , 2009, Yonsei medical journal.

[20]  Bruno Zanotti,et al.  Proteomic studies on low- and high-grade human brain astrocytomas. , 2005, Journal of proteome research.

[21]  P. Black,et al.  Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  W. Hamel,et al.  Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma , 2004, Journal of Neuro-Oncology.

[23]  S. Niclou,et al.  Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.

[24]  M. Oshimura,et al.  Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.

[25]  Friedrich Lottspeich,et al.  ICPL labeling strategies for proteome research. , 2011, Methods in molecular biology.

[26]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[27]  Chae-Yong Kim,et al.  Tissue Expression of Manganese Superoxide Dismutase Is a Candidate Prognostic Marker for Glioblastoma , 2009, Oncology.

[28]  J. Mosser,et al.  Isolation of a new cell population in the glioblastoma microenvironment , 2012, Journal of Neuro-Oncology.

[29]  Identification of Glioma Neovascularization-related Proteins by Using MALDI-FTMS and Nano-LC Fractionation to Microdissected Tumor Vessels* , 2007, Molecular & Cellular Proteomics.

[30]  H. Sandler,et al.  Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. , 1991, Journal of neurosurgery.

[31]  Hans-Peter Lenhof,et al.  Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. , 2009, Journal of proteome research.

[32]  J. Kellermann.  ICPL--isotope-coded protein label. , 2008, Methods in molecular biology.

[33]  G. Iacob,et al.  Current data and strategy in glioblastoma multiforme , 2009, Journal of medicine and life.

[34]  Yu Shyr,et al.  Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.

[35]  A. Schmidt,et al.  A novel strategy for quantitative proteomics using isotope‐coded protein labels , 2005, Proteomics.

[36]  Akira Yamaura,et al.  Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis , 2004, Cancer Research.

[37]  A. Vortmeyer,et al.  Protein patterns and proteins that identify subtypes of glioblastoma multiforme , 2004, Oncogene.

[38]  E. Wawrousek,et al.  Exacerbation of retinal degeneration in the absence of alpha crystallins in an in vivo model of chemically induced hypoxia. , 2008, Experimental eye research.

[39]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[40]  P. Svenningsson,et al.  The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2‐20 and peptides as sample quality indicators , 2007, Proteomics.

[41]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[42]  Philippe Menei,et al.  Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. , 2012, Journal of proteomics.